| Cat. No. |
Product Name |
Information |
| PC-42553 |
Canertinib dihydrochloride
pan-ErbB inhibitor
|
Canertinib dihydrochloride (CI-1033, PD183805) is a potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay. |
| PC-45813 |
Neratinib
EGFR inhibitor
|
Neratinib (HKI-272) is a potent, highly selective, irreversible HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays. |
| PC-22088 |
Icotinib hydrochloride
EGFR inhibitor
|
Icotinib hydrochloride (BPI-2009H) is a potent and specific EGFR inhibitor with IC50 of 5 nM, also inhibits mutant EGFRL858R, EGFR L858R/T790M, EGFR T790M and EGFR L861Q. |
| PC-22087 |
Icotinib
EGFR inhibitor
|
Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with IC50 of 5 nM, also inhibits mutant EGFRL858R, EGFR L858R/T790M, EGFR T790M and EGFR L861Q. |
| PC-21851 |
DDC4002
mutant EGFR inhibitor
|
DDC4002 is a potent, selective and allosteric EGFR inhibitor, shows selectivity against L858R/T790M/C797S EGFR mutants with IC50 of 39-50 nM, does not inhibit WT EGFR. |
| PC-21850 |
EAI001
mutant EGFR inhibitor
|
EAI001 is a potent, mutant-selectiveepidermal growth factor receptor (EGFR) allosteric inhibitor with IC50 value of 24 nM for EGFRL858R/T790M. |
| PC-21841 |
AG1478
EGFR inhibitor
|
AG1478 (Tyrphostin AG-1478) is a potent, selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. |
| PC-21782 |
HSL119
HUNK inhibitor
|
HSL119 (HSL 119) is a potent and selective hormonally upregulated neu-associated kinase (HUNK) inhibitor, completely inhibits HUNK kinase activity at 1 uM in biochemical assays. |
| PC-21566 |
BDTX-1535
EGFR inhibitor
|
BDTX-1535 is a 4th generation, irreversible, CNS penetrant, potent, wild type sparing EGFR inhibitor, targets a family of oncogenic EGFR extracellular domain alterations and amplification in GBM, and EGFR resistance mutations in NSCLC. |
| PC-21465 |
BI-8128
EGFR inhibitor
|
BI-8128 is a potent, selective, reversible and orally bioavailable fourth generation EGFR inhibitor, potently inhibits oncogenic EGFR variants del19 and L858R as well as the acquired EGFR resistance mutations T790M and C797S. |
| PC-21322 |
STX-721
EGFR inhibitor
|
STX-721 is a potent, selective, next-generation, orally active inhibitor of EGFR exon 20 insertion mutations. |
| PC-21316 |
EGFR inhibitor 9
EGFR inhibitor
|
EGFR inhibitor 9 is a potent, selective, brain-penetrant and orally bioavailable EGFR inhibitor, exhibits potent activity in osimertinib-resistant cell lines bearing L858R/C797S and exon19del/C797S EGFR resistance mutations. |
